AVX901 / AlphaVax - LARVOL DELTA

A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer (clinicaltrials.gov) - P2 | N=8 | Terminated | Sponsor: Herbert Lyerly | Active, not recruiting ➔ Terminated; Enrollment issue

Trial termination • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Oncology • Solid Tumor

A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer (clinicaltrials.gov) - P2 | N=8 | Active, not recruiting | Sponsor: Herbert Lyerly | Trial completion date: Dec 2024 ➔ Dec 2025

Trial completion date • Breast Cancer • HER2 Breast Cancer • Oncology • Solid Tumor

A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer (clinicaltrials.gov) - P2 | N=9 | Active, not recruiting | Sponsor: Herbert Lyerly | Recruiting ➔ Active, not recruiting | N=39 ➔ 9

Enrollment change • Enrollment closed • Metastases • Breast Cancer • HER2 Breast Cancer • Oncology • Solid Tumor

A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer (clinicaltrials.gov) - P2 | N=39 | Recruiting | Sponsor: Herbert Lyerly | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Dec 2022 ➔ Dec 2023

Metastases • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • Immunology • Oncology • Solid Tumor

A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer (clinicaltrials.gov) - P2; N=39; Recruiting; Sponsor: Herbert Lyerly; Trial completion date: Oct 2022 ➔ Oct 2023; Trial primary completion date: Oct 2021 ➔ Oct 2022

Clinical • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • Immunology • Oncology • Solid Tumor

Immunotherapy for the Breast Cancer treatment: Current Evidence and Therapeutic Options. (PubMed, Endocr Metab Immune Disord Drug Targets) - "Although, commonly used treatments like trastuzumab/pertuzumab for human epidermal growth factor receptor 2 (Her2) positive and hormone therapy for estrogen receptor (ER) positive and/or progesterone receptor (PR) positive BC are specific but triple negative breast cancer (TNBC) cases remain a great challenge for treatment measures. Immune checkpoint inhibitors (anti-PD-1/ anti-CTLA-4) and anti-cancer vaccines (NeuVax, Muc-1, AVX901, INO-1400 and CEA), either alone or in combination with other therapies have created new paradigm in therapeutic world. In this review, we highlighted the current immunotherapeutic aspects and their ongoing trials towards the better treatment regimen for BC."

Journal • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Immune Modulation • Immunology • Inflammation • Oncology • Solid Tumor • Triple Negative Breast Cancer • ER • HER-2 • MUC1 • PGR

A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer (clinicaltrials.gov) - P2; N=39; Recruiting; Sponsor: Herbert Lyerly; Trial completion date: Oct 2021 ➔ Oct 2022; Trial primary completion date: Oct 2020 ➔ Oct 2021

Clinical • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • Immunology • Oncology • Solid Tumor • HER-2

A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer (clinicaltrials.gov) - P2; N=39; Not yet recruiting; Sponsor: Herbert Lyerly; Initiation date: Oct 2018 ➔ Feb 2019

Clinical • Trial initiation date • Biosimilar • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor

A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer (clinicaltrials.gov) - P2; N=39; Not yet recruiting; Sponsor: Herbert Lyerly

Clinical • New P2 trial • P2 data

A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer (clinicaltrials.gov) - P2; N=39; Recruiting; Sponsor: Herbert Lyerly; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open